Evidence map›Paper›PMID 41425830›Full record

ArticleBMJ neurology open2025

Blood biomarkers of seizures in epilepsy: machine learning reveals altered plasma proteome.

Sarah Akel, Saman Hosseini Ashtiani, Mayuresh Anant Sarangdhar, Markus Axelsson, Johan Zelano

Abstract read
In one paragraph

Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah Akel *Department of Clinical Neuroscience, University of Gothenburg Sahlgrenska Academy, Gothenburg, Västra Götaland County, Sweden.ORCID https://orcid.org/0000-0003-3806-8724
Saman Hosseini Ashtiani *Department of Clinical Neuroscience, University of Gothenburg Sahlgrenska Academy, Gothenburg, Västra Götaland County, Sweden.
Mayuresh Anant SarangdharDepartment of Clinical Neuroscience, University of Gothenburg Sahlgrenska Academy, Gothenburg, Västra Götaland County, Sweden.
Markus AxelssonDepartment of Clinical Neuroscience, University of Gothenburg Sahlgrenska Academy, Gothenburg, Västra Götaland County, Sweden.
Johan ZelanoDepartment of Clinical Neuroscience, University of Gothenburg Sahlgrenska Academy, Gothenburg, Västra Götaland County, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fluid biomarkers are emerging for diagnosis and monitoring in neurology. Epilepsy remains an exception, despite seizures being known to result in inflammation and altered levels of several brain proteins. We aimed to identify candidate biomarkers through a comprehensive proteomic analysis of proteins associated with brain disease or inflammation. Methods: Cross-sectional analysis of plasma from adult participants in the PREDICT biobank study in Västra Götaland, Sweden. Participants aged 18-50 with epilepsy and seizures (n=88) were compared with those with epilepsy who had been seizure-free (n=88) for >1 year using four OlinkExplore384 panels, analysing 1447 proteins. Results: Two machine-learning models, one linear and one non-linear, identified protein expression differences through feature selection, resulting in 51 unique proteins between the models. Twenty-three proteins were considered differentially expressed after false discovery rate adjustment (p≤0.05), including neurofilament light and several cytokines. Protein-protein interaction (PPI) analysis identified clusters among 51 unique proteins, with the largest clusters primarily associated with inflammatory processes. In addition, machine learning-independent gene set enrichment analysis identified 34 gene sets, mainly related to immune and inflammatory processes, that were also enriched in participants with seizures. Conclusions: Persons with epilepsy and seizures had different plasma protein profiles compared with those seizure-free, primarily suggesting altered inflammatory/immune processes. This fits well with growing evidence of inflammation as a key process in epilepsy. In addition to new therapeutic targets, immune processes need further exploration as candidate biomarkers for monitoring of treatment response in epilepsy.

Indexed as

EPILEPSY

Identifiers

PMID41425830
PMCPMC12716561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.